Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease

被引：43
|
作者：
Meister, M. [1 ]
Choyke, P. [2 ]
Anderson, C. [3 ]
Patel, U. [1 ]
机构：
[1] St George Hosp, Dept Radiol, London SW17 0QT, England
[2] St George Hosp, Dept Urol, London SW17 0QT, England
[3] NIH, Dept Radiol, Bethesda, MD 20892 USA
来源：
CLINICAL RADIOLOGY | 2009年 / 64卷 / 06期
关键词：
PARENCHYMAL SPARING SURGERY; BOSNIAK CATEGORY-III; CELL CARCINOMA; VHL GENE; RADIOFREQUENCY ABLATION; PROGNOSTIC-SIGNIFICANCE; IMAGING FEATURES; TUMOR SIZE; CANCER; CT;
D O I：
10.1016/j.crad.2008.10.010
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Von Hippel-Lindau disease (VHL) is a rare, autosomal-dominant condition that predisposes patients to developing renal cysts and tumours. VHL is the most common of the hereditary renal cancer syndromes, and is exclusively associated with the clear cell histological subtype of renal cell carcinoma. This review focuses on the genetics, surveillance, and management of complex renal masses in VHL. The current status of renal cyst analysis in general. and in the context of VHL is also reviewed. (C) 2008 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：589 / 600
页数：12
相关论文
共 50 条
  • [11] Patterns of intervention for renal lesions in von Hippel-Lindau disease
    Matin, Surena F.
    Ahrar, Kamran
    Wood, Christopher G.
    Daniels, Molly
    Jonasch, Eric
    BJU INTERNATIONAL, 2008, 102 (08) : 940 - 945
  • [12] Active surveillance of renal masses in von Hippel-Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months
    Zhang, Jin
    Pan, Jia-Hua
    Dong, Bai-Jun
    Xue, Wei
    Liu, Dong-ming
    Huang, Yi-Ran
    FAMILIAL CANCER, 2012, 11 (02) : 209 - 214
  • [13] Copy Number Profiling in Von Hippel-Lindau Disease Renal Cell Carcinoma
    Shuib, Salwati
    Wei, Wenbin
    Sur, Hariom
    Morris, Mark R.
    McMullan, Dominic
    Rattenberry, Eleanor
    Meyer, Esther
    Maxwell, Patrick H.
    Kishida, Takeshi
    Yao, Masahiro
    Latif, Farida
    Maher, Eamonn R.
    GENES CHROMOSOMES & CANCER, 2011, 50 (07) : 479 - 488
  • [14] Surgical Management of von Hippel-Lindau Disease: Urologic Considerations
    Reed, Amanda Beth
    Parekh, Dipen. L.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 18 (01) : 157 - +
  • [15] Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results
    Iwamoto, Yoichi
    Kanda, Hideki
    Yamakado, Koichiro
    Soga, Norihito
    Arima, Kiminobu
    Takeda, Kan
    Sugimura, Yoshiki
    FAMILIAL CANCER, 2011, 10 (03) : 529 - 534
  • [16] Ocular clusterin expression in von Hippel-Lindau disease
    Zhou, Min
    Shen, Defen
    Head, James E.
    Chew, Emily Y.
    Chevez-Barrios, Patricia
    Green, W. Richard
    Chan, Chi-Chao
    MOLECULAR VISION, 2007, 13 (239-41): : 2129 - 2136
  • [17] Ocular Manifestations of von Hippel-Lindau Disease
    Ruppert, Misty D.
    Gavin, Meredith
    Mitchell, Kelly T.
    Peiris, Alan N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (08)
  • [18] Neurosurgical considerations in von Hippel-Lindau disease
    Beitner, M. M.
    Winship, I.
    Drummond, K. J.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2011, 18 (02) : 171 - 180
  • [19] Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond
    Curry, Lauren
    Soleimani, Maryam
    FUTURE ONCOLOGY, 2024, 20 (18) : 1251 - 1266
  • [20] Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease?
    Naber, Myrthe R.
    Ahmad, Saya
    Stuart, Annemarie A. Verrijn
    Giles, Rachel H.
    Valk, Gerlof D.
    van Leeuwaarde, Rachel S.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2022, 6 (02)
12345